Supernus Pharmaceuticals filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company focused on central nervous system diseases. Recent Form 8-K reports cover operating results, conference-call related earnings releases, material definitive agreements, executive compensation arrangements, and other material events tied to the company's CNS product portfolio and corporate obligations.
Proxy materials describe annual meeting voting matters, director elections, advisory executive compensation votes, auditor ratification, and equity incentive plan amendments. The filings also identify the company's common stock structure, exchange listing, shareholder voting mechanics, governance practices, and capital-structure disclosures.
Supernus Pharmaceuticals (SUPN) Form 144 notice reports an intended sale of 24,150 common shares through Morgan Stanley Smith Barney with an aggregate market value of $1,088,440.50, based on approximately 56,073,088 shares outstanding. The filing lists the approximate sale date as 08/28/2025.
The securities were acquired and are being sold on 08/28/2025 following the exercise of stock options, with payment in cash to the issuer. The filing also discloses multiple recent Rule 10b5-1 sales by Jack A. Khattar in August 2025 totaling sizable share amounts and gross proceeds across several dates, indicating ongoing disposition of shares by this insider.
Padmanabh P. Bhatt, Senior Vice President of IP and Chief Scientific Officer at Supernus Pharmaceuticals (SUPN), reported equity transactions dated 08/25/2025. The report shows the settlement of 1,250 shares upon vesting of Performance Share Units awarded on February 23, 2023, and 581 shares were withheld by the company to satisfy tax withholding at an indicated price of $41.46 per share. Following these transactions, the reporting person beneficially owned 13,718 shares of common stock. The filing explains the PSUs vested after achievement of individual performance objectives established June 12, 2023. The form was signed by an attorney-in-fact on behalf of the reporting person on 08/27/2025.
Frank Mottola, SVP, Quality, GMP, Ops, IT at Supernus Pharmaceuticals (SUPN), reported option exercise and an immediate sale on 08/25/2025. He exercised an employee stock option with a $12.98 exercise price to acquire 14,000 shares and simultaneously sold 14,000 shares at $44.51.
After these transactions the filing shows the Reporting Person beneficially owned 15,496 shares (which includes 345 shares from the company Employee Stock Purchase Plan). The filing also notes the exercised option vests in four equal annual installments beginning March 1, 2017, and that the underlying shares were sold prior to option expiration on March 1, 2026.
Charles W. Newhall III, a director of Supernus Pharmaceuticals, Inc. (SUPN), reported the sale of 1,000 shares of the issuer's common stock on 08/25/2025 pursuant to a 10b5-1 trading plan adopted March 3, 2025. The filing shows a weighted average sale price of $45 (individual trades ranged $45.00–$45.01) and indicates the reporting person beneficially owned 133,232 shares after the transaction. The Form 4 was signed by an attorney-in-fact on 08/27/2025 and was filed as a single-person report.
Insider transactions by Supernus Pharmaceuticals (SUPN): Jack A. Khattar, President & CEO and a director, exercised 1,611 employee stock options with an exercise price of $12.98 on 08/25/2025, acquiring 1,611 shares. The exercise was made pursuant to an employee option that vested in four equal installments beginning March 1, 2017. On the same date he sold 1,000 shares at an average price of $45.00 (reported weighted average $45, range $45.00–$45.01).
Following these transactions Khattar beneficially owned 1,071,459 shares directly and 1,005,600 shares indirectly through the KBT Trust. The exercise and sale were executed under a 10b5-1 trading plan adopted November 14, 2024. The Form 4 was signed by an attorney-in-fact on 08/27/2025.
Supernus Pharmaceuticals (SUPN) insider sale notice: An officer filed a Form 144 to sell 10,650 shares of common stock on NASDAQ through Morgan Stanley Smith Barney. The 10,650 shares were acquired and are to be sold following an exercise of stock options with cash payment on the same date. The filing also discloses prior 10b5-1 plan sales by the same person totaling 142,500 shares over the past three months, generating aggregate gross proceeds of approximately $5,995,737.40. The current proposed sale lists an aggregate market value of $472,008.00.
Charles W. Newhall III, a director of Supernus Pharmaceuticals, Inc. (SUPN), reported the sale of 1,412 shares of the company’s common stock on 08/22/2025. The sales were made pursuant to a Rule 10b5-1 trading plan adopted March 3, 2025, and the price reported is a weighted average of $45, with individual sale prices ranging from $45.00 to $45.01. After the reported disposition, the reporting person beneficially owned 134,232 shares, held directly.
The filing is signed on behalf of the reporting person by an attorney-in-fact, Timothy C. Dec, dated 08/26/2025. The reporting person offers to provide details of the number of shares sold at each separate price within the disclosed range upon request.
Insider transaction by Supernus Pharmaceuticals (SUPN) officer. Senior Vice-President & Chief Financial Officer Timothy C. Dec reported the sale of 11,780 shares of Supernus common stock on 08/22/2025 at a weighted average price of $44.49 per share. Following the disposition, the reporting person beneficially owned 1,246 shares in total, which includes 345 shares acquired through the company's Employee Stock Purchase Plan. The Form 4 discloses the sale as a non-derivative transaction and provides a price range for individual sale prices within $44.40 to $44.66.
Jack A. Khattar, President, CEO and a director of Supernus Pharmaceuticals, Inc. (SUPN), reported transactions on 08/22/2025 under Form 4. He exercised employee stock options to acquire 2,415 shares at an exercise price of $12.98 per share, and sold 1,500 shares at a weighted average price of $45.00 (sales executed at prices ranging from $45.00 to $45.01). Following these transactions his direct beneficial ownership is reported as 1,070,848 shares and he also has 1,005,600 shares indirectly beneficially owned through the KBT Trust. The exercised options relate to an award exercisable through 03/01/2026 and vesting began 03/01/2017. The sale was made pursuant to a 10b5-1 trading plan adopted on November 14, 2024. The Form 4 was signed by an attorney-in-fact on 08/26/2025.
Insider sale notice for SUPN. This Form 144 reports a proposed sale of 1,000 common shares on 08/25/2025 by a person who acquired those shares the same day through exercise of stock options and paid in cash. The broker is Morgan Stanley Smith Barney LLC and the filing lists an aggregate market value of $44,880.00 for the shares. The filing states 56,073,000 shares outstanding and identifies the securities exchange as NASDAQ. The filing also discloses prior 10b5-1 sales by Jack A Khattar during August 2025 totaling 141,500 shares for gross proceeds of $5,361,736.40 across four transactions.